EA200802444A1 - Стабилизированные фармацевтические композиции, содержащие фезотеродин - Google Patents

Стабилизированные фармацевтические композиции, содержащие фезотеродин

Info

Publication number
EA200802444A1
EA200802444A1 EA200802444A EA200802444A EA200802444A1 EA 200802444 A1 EA200802444 A1 EA 200802444A1 EA 200802444 A EA200802444 A EA 200802444A EA 200802444 A EA200802444 A EA 200802444A EA 200802444 A1 EA200802444 A1 EA 200802444A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phesterodine
pharmaceutical compositions
compositions containing
stabilized pharmaceutical
stabilized
Prior art date
Application number
EA200802444A
Other languages
English (en)
Other versions
EA015909B9 (ru
EA015909B1 (ru
Inventor
Кристоф Арт
Ханс-Юрген Мика
Михаэль Коменда
Ханс Линднер
Фатима Бикане
Керстин Паулус
Майке Ирнгартингер
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200802444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200802444A1 publication Critical patent/EA200802444A1/ru
Publication of EA015909B1 publication Critical patent/EA015909B1/ru
Publication of EA015909B9 publication Critical patent/EA015909B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящая заявка относится к фармацевтической композиции, содержащей фезотеродин или его фармацевтически приемлемые соль или сольват и стабилизатор, выбранный из группы, состоящей из ксилита, сорбита, полидекстрозы, изомальта и декстрозы.
EA200802444A 2006-06-09 2007-06-06 Стабилизированные фармацевтические композиции, содержащие фезотеродин EA015909B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011941 2006-06-09
EP06011943 2006-06-09
EP06011942 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Publications (3)

Publication Number Publication Date
EA200802444A1 true EA200802444A1 (ru) 2009-06-30
EA015909B1 EA015909B1 (ru) 2011-12-30
EA015909B9 EA015909B9 (ru) 2012-03-30

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802444A EA015909B9 (ru) 2006-06-09 2007-06-06 Стабилизированные фармацевтические композиции, содержащие фезотеродин

Country Status (37)

Country Link
EP (1) EP2029134B1 (ru)
JP (2) JP4743321B2 (ru)
KR (1) KR101316773B1 (ru)
CN (1) CN101466371B (ru)
AP (1) AP2416A (ru)
AR (1) AR061289A1 (ru)
AT (1) ATE517619T1 (ru)
AU (1) AU2007255408B2 (ru)
BR (1) BRPI0712865B1 (ru)
CA (1) CA2652712C (ru)
CR (1) CR10494A (ru)
CU (1) CU23850B1 (ru)
CY (1) CY1111934T1 (ru)
DK (1) DK2029134T3 (ru)
EA (1) EA015909B9 (ru)
EC (1) ECSP089010A (ru)
ES (1) ES2370943T3 (ru)
GT (1) GT200800276A (ru)
HR (1) HRP20110776T1 (ru)
IL (2) IL195732A (ru)
MA (1) MA30504B1 (ru)
MX (1) MX2008015736A (ru)
MY (1) MY146574A (ru)
NI (1) NI200800318A (ru)
NL (1) NL2000690C2 (ru)
NO (1) NO341980B1 (ru)
NZ (1) NZ572616A (ru)
PE (2) PE20120476A1 (ru)
PL (1) PL2029134T3 (ru)
PT (1) PT2029134E (ru)
RS (1) RS51973B (ru)
SI (1) SI2029134T1 (ru)
TN (1) TNSN08505A1 (ru)
TW (2) TWI520735B (ru)
UY (1) UY30394A1 (ru)
WO (1) WO2007141298A1 (ru)
ZA (1) ZA200806411B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086103A1 (en) * 2008-04-04 2011-04-14 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI520732B (zh) 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
WO2014006636A2 (en) * 2012-07-02 2014-01-09 Hetero Research Foundation Stable compositions of fesoterodine
EA032515B1 (ru) 2012-11-02 2019-06-28 Марри Энд Пул Энтерпрайзес, Лтд. Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
US20160081936A1 (en) 2013-04-16 2016-03-24 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
EP3784217A1 (en) 2018-04-26 2021-03-03 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2020243120A1 (en) 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation
AU2021299197A1 (en) * 2020-06-30 2023-02-02 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
WO2023145486A1 (ja) * 2022-01-28 2023-08-03 沢井製薬株式会社 フェソテロジンフマル酸塩含有製剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757002B2 (en) 1998-03-03 2003-01-30 Eli Lilly And Company Pharmaceutical compositions containing the phospholipase inhibitor sodium ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1- phenylmethyl)-1H-indol-4-YL)oxy)acetate
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
ATE517619T1 (de) 2011-08-15
GT200800276A (es) 2009-06-18
NO20090141L (no) 2009-01-09
DK2029134T3 (da) 2011-10-17
CA2652712C (en) 2014-04-01
TWI397409B (zh) 2013-06-01
JP2011140498A (ja) 2011-07-21
EP2029134B1 (en) 2011-07-27
AU2007255408A1 (en) 2007-12-13
PE20120476A1 (es) 2012-04-20
MA30504B1 (fr) 2009-06-01
TW201336491A (zh) 2013-09-16
NL2000690A1 (nl) 2007-12-11
CU20080235A7 (es) 2011-04-26
TNSN08505A1 (fr) 2010-04-14
ES2370943T3 (es) 2011-12-23
AP2008004673A0 (en) 2008-12-31
IL220800A (en) 2015-03-31
NZ572616A (en) 2010-11-26
UY30394A1 (es) 2007-11-30
RS51973B (sr) 2012-02-29
PL2029134T3 (pl) 2011-12-30
EP2029134A1 (en) 2009-03-04
TW200814992A (en) 2008-04-01
PE20080331A1 (es) 2008-06-19
JP2009539802A (ja) 2009-11-19
CN101466371B (zh) 2011-10-05
WO2007141298A1 (en) 2007-12-13
KR20090026135A (ko) 2009-03-11
AR061289A1 (es) 2008-08-20
CY1111934T1 (el) 2015-11-04
AU2007255408B2 (en) 2013-03-14
CA2652712A1 (en) 2007-12-13
EA015909B9 (ru) 2012-03-30
IL195732A (en) 2013-09-30
HRP20110776T1 (hr) 2011-11-30
MX2008015736A (es) 2009-01-09
PT2029134E (pt) 2011-11-02
NO341980B1 (no) 2018-03-05
NI200800318A (es) 2011-01-12
ECSP089010A (es) 2009-01-30
BRPI0712865A2 (pt) 2012-12-18
EA015909B1 (ru) 2011-12-30
CN101466371A (zh) 2009-06-24
JP4743321B2 (ja) 2011-08-10
CR10494A (es) 2009-01-19
MY146574A (en) 2012-08-30
TWI520735B (zh) 2016-02-11
NL2000690C2 (nl) 2008-04-01
SI2029134T1 (sl) 2012-01-31
BRPI0712865B1 (pt) 2021-08-17
HK1128626A1 (en) 2009-11-06
ZA200806411B (en) 2009-05-27
CU23850B1 (es) 2012-10-15
AP2416A (en) 2012-06-01
JP4781489B2 (ja) 2011-09-28
KR101316773B1 (ko) 2013-10-15
IL195732A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
EA200802444A1 (ru) Стабилизированные фармацевтические композиции, содержащие фезотеродин
NO20084368L (no) Stabile emulsjonsformuleringer
DK2068822T4 (da) Selvpræserverede vandige farmaceutiske sammensætninger
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
CR8788A (es) Orodispersible pharmaceutical compositions for oromucosal or sublingual administration of agomelatine
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
NO345139B1 (no) Florizinanaloger som inhibitorer av glukosekotransportør 2 og farmasøytisk sammensetning derav
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
JP2011527299A5 (ru)
WO2007122581A3 (en) Compositions and kits of phenylephrine
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0821373A2 (pt) Composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
BRPI0719772A2 (pt) Compostos, composições fungicidas para combater fungos nocivos fitopatogênicos, agente, método para combater fungos nocivos fitopatogênicos, semente, uso dos compostos, e, composição farmacêutica.
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
BRPI0411820B8 (pt) composição farmacêutica para administração parenteral, e seus usos
UA94107C2 (ru) Стабилизированная фармацевтическая композиция фезотеродина
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
ITMI20061741A1 (it) Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
DOP2008000067A (es) Composiciones farmaceuticas estabilizada que comprenden fesoterodina.
NO20090448L (no) En aminoisoquinolin trombin inhibitor med forbedret biotilgjengelighet

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
ND4A Extension of term of a eurasian patent
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title